China National Pharmaceutical Group Co., Ltd. (Sinopharm) is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with 128,000 employees and a full chain in the industry covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services.
Sinopharm owns over 1,100 subsidiaries and 6 listed companies which are Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., China National Accord Medicines Corporation Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd., and China Traditional Chinese Medicine Holdings Co., Ltd.
The past years witnessed Sinopharm’s steady and sound development. From 2009to 2018, the CAGR of revenue and total assets reached 24.24% and 30.54% respectively. Sinopharm ranked 169th in Fortune Global 500 and the revenue of 2018 amounted to nearly 400 billion yuan..
Sinopharm has built a nationwide logistic and distributing network for drugs and medical devices and equipment, including 5logistic hubs, more than 40 provincial-level centers and over 240 municipal-level logistic sites. By establishing the smart medical service system, Sinopharmdelivers quality servicesto more than 230,000 corporate clients.
Sinopharm has an applied pharmaceutical research institute and an engineering design institute, both taking a leading position in China. Two Academicians of Chinese Academy of Engineering, 11 national R&D institutes, 44 provincial-level technology centers and over 5,000 scientists have made remarkable achievements.Sinopharm also chaired in setting over 530 national technical criteria, among which the EV71 vaccine, a first category new drug of China with Sinopharm holding complete independent intellectual property right, reduces the morbidity of hand-foot-and mouth disease among Chinese children. The R&D and launch of sIPV ensures the progress of the national immunization program for polio.
Sinopharm has built up manufacturing and medicinal materials sites for biological drugs, narcotic and psychotropic drugs, anti-infectious drugs, oncology drugs, cardio-vascular drugs and respiratory drugs. Some of the production lines have been approved by the US FDA and EU authorities, and prequalified by WHO.
As world's 6th largest vaccine manufacturer, Sinopharm is able to produce all the vaccines in the National Vaccination Program and is the supplier of over 80% vaccines used in the Expanded Program on Immunization in China.
Sinopharm leads in TCM sector by establishing an integrated TCM industry chain that covers planting, R&D, pieces for decoction, formulated instant granules, and preparations. It is able to produce over 900 medicines,owns 15 China Time-honored Brands and 4 National Intangible Cultural Heritage medicines.
Sinopharmhas fostered 30 highly recognized events represented by CMEF (China International Medical Equipment Fair), serving the entire chain and many subdivisions concerning healthcare. These exhibitions and conferences have become a platform for exchange and cooperation that advances the whole industry.
Sinopharm explored a new model of drugstores with extensive healthcare services. There are over 5,100 chain drugstores under the brands of Guoda, Jinxiang, Dadesheng and Tianyitang, providing convenientaccess for customers. Sinopharm forms a healthcare network consisting of regional healthcare groups in provinces of Henan, Hubei, Liaoning, and Heilongjiang. Sinopharm provides easier access to healthcare services for the people in dozens of our medical institutions with more than 10,000 beds in total.
Sinopharm broadens its international cooperation by founding 26 joint ventures with world-renowned pharmaceutical companies andtrading with more than 120 countries and regions, including60 Belt and Road countries.
The JE vaccine of which Sinopharm owns complete independent intellectual property right has been listed into the procurement catalog by the UN organizations to benefit the whole world.Sinopharm’sproduction sites in Vietnam and Malaysia, along withthe China-aided hospitals and mobile clinicsconstructed by Sinopharm in Myanmar and Cambodia,not only provide jobs for the local people, but also make greatcontributions to their well-beings.
As healthcare-centered financial services develop, an industry-and-finance model with Sinopharm features takes shape.
Guided by the core value of “all for health, health for all”, Sinopharm shoulders the social responsibility of national medical and pharmaceutical reserve on a long-term basis with pride. In times of epidemics and disasters, it provides medicines, bio-products, traditional Chinese medicines, and medical devices promptly to the stricken areas not only at home, but also abroad as in Ecuador earthquake relief and in Myanmar influenza A/H1N1 prevention and control, contributing to ensure a sound public health condition for the people.
Sinopharm acts as the president enterprise in many influential associations such as China Pharmaceutical Industry Association, China National Narcotic Drugs Association, China Association of Pharmaceutical Commerce, etc., and plays its role in preventing diseases, safeguarding people’s health, and advancing the whole industry.